Pivmecillinam in complicated urinary infections failing to respond to conventional therapy.
Forty-three patients with a history of recurrent urinary infections, many of whom had renal involvement and had recently failed treatment, were then treated with pivmecillinam (400 mg 8-hourly for seven days). One week after the end of treatment the bacteriological cure rate was 72.1%. During the following four weeks, however, several of the cured patients relapsed, so that the cure rate five weeks after the end of treatment was only 46%. Thus, it is recommended that such patients should begin prophylactic treatment if found to be abacteriuric after the one week follow-up. Pivmecillinam was extremely well tolerated.
D000328:Adult; D000561:Amdinocillin Pivoxil / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001437:Bacteriuria / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000627:therapeutic use*; D011512:Proteus Infections / Q000188:drug therapy; D011513:Proteus mirabilis; D012008:Recurrence; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013292:Streptococcus agalactiae; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004338:Drug Combinations; D000561:Amdinocillin Pivoxil; D010397:Penicillanic Acid